- Direction
- Stable
- Own history
- 62th
- Peers
- 78th
- Persistence
- TRANSIENT
· Services-Medical Laboratories
RESEARCH SNAPSHOTNatera, Inc.'s latest supported as-filed period reports revenue of $752.8M, 37.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 8.43% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 7.28% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 37.72% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 10.67% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -10.07% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 30.30% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 37.7%; Operating margin moved 1012 bp higher; Operating income increased 31.3%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Inventory increased 48.0%; Inventory / revenue moved 74 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 144.9%; Capex / revenue moved 369 bp higher.
2 evidence-backed componentsTotal assets changed +51.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
NTRA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001697362-26-000021SEC ↗4Oct 29, 2026Period Oct 27, 20260001646649-26-000040SEC ↗4Oct 29, 2026Period Oct 27, 20260001646382-26-000026SEC ↗4Oct 29, 2026Period Oct 27, 20260001711968-26-000027SEC ↗4Oct 29, 2026Period Oct 27, 20260001857843-26-000030SEC ↗4Oct 29, 2026Period Oct 27, 20260002010019-26-000035SEC ↗4Oct 29, 2026Period Oct 27, 20260002010135-26-000025SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 30, 2026Filed Oct 30, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Open Market SaleDirect | 1,906 | $426 | $811,098 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 30, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Open Market SaleDirect | 865 | $427 | $369,245 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 30, 2026 | Brophy Michael BurkesCHIEF FINANCIAL OFFICER | Open Market SaleDirect | 313 | $425 | $133,126 | Form 4 ↗ |
| Oct 28, 2026Filed Oct 29, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open Market SaleDirect | 1,162 | $426 | $495,408 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 13.70% · OPTIONAL
Trade receivables changed +36.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +43.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Revenue changed +37.7% from the comparable as-filed period.
Inventory changed +48.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating margin changed +1012 basis points from the comparable as-filed period.
Research & development changed +55.8% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001697362-26-000020| Oct 28, 2026Filed Oct 29, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 187 | $426 | $79,726 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | Open Market SaleDirect | 1,010 | $406 | $410,060 | Form 4 ↗ |
| Oct 27, 2026Filed Oct 29, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 291 | $406 | $118,146 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 165 | $417 | $68,751 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 255 | $416 | $105,995 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 200 | $407 | $81,300 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 962 | $408 | $392,745 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 627 | $410 | $257,003 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 605 | $411 | $248,847 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 211 | $412 | $86,974 | Form 4 ↗ |
| Oct 21, 2026Filed Oct 23, 2026 | Sheena JonathanDirector | Open Market SaleDirect | 125 | $413 | $51,631 | Form 4 ↗ |
| Oct 16, 2026Filed Oct 20, 2026 | Sheena JonathanDirector | Open Market SaleIndirect | 215 | $399 | $85,858 | Form 4 ↗ |
| Oct 16, 2026Filed Oct 20, 2026 | Sheena JonathanDirector | Open Market SaleIndirect | 280 | $401 | $112,360 | Form 4 ↗ |
| Oct 16, 2026Filed Oct 20, 2026 | Sheena JonathanDirector | Open Market SaleIndirect | 90 | $404 | $36,383 | Form 4 ↗ |
| Oct 16, 2026Filed Oct 20, 2026 | Sheena JonathanDirector | Open Market SaleIndirect | 50 | $405 | $20,258 | Form 4 ↗ |
| Oct 16, 2026Filed Oct 20, 2026 | Sheena JonathanDirector | Open Market SaleIndirect | 35 | $407 | $14,232 | Form 4 ↗ |